INmune Bio (NASDAQ:INMB) Rating Increased to Strong-Buy at Lucid Cap Mkts

Lucid Cap Mkts upgraded shares of INmune Bio (NASDAQ:INMB) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Separately, Wall Street Zen upgraded INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.00.

INmune Bio Stock Performance

Shares of INMB opened at $1.42 on Wednesday. INmune Bio has a 52-week low of $1.16 and a 52-week high of $11.64. The firm has a market cap of $37.75 million, a price-to-earnings ratio of -0.67 and a beta of 0.77. The business’s fifty day moving average is $1.49 and its 200-day moving average is $1.72.

Institutional Trading of INmune Bio

A number of hedge funds and other institutional investors have recently modified their holdings of INMB. XTX Topco Ltd increased its holdings in shares of INmune Bio by 240.9% during the second quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after buying an additional 88,928 shares in the last quarter. Westside Investment Management Inc. boosted its holdings in shares of INmune Bio by 384.0% during the 3rd quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after acquiring an additional 82,075 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of INmune Bio by 1,042.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock valued at $169,000 after acquiring an additional 66,700 shares in the last quarter. State Street Corp grew its position in INmune Bio by 22.3% during the 4th quarter. State Street Corp now owns 347,259 shares of the company’s stock worth $542,000 after acquiring an additional 63,426 shares during the last quarter. Finally, Jain Global LLC bought a new stake in INmune Bio during the 4th quarter worth $66,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.